AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9444446
Drug: amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5 mg QD (titrated to 10 mg if needed)
Trial: 2735335
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g four times per day
Trial: 2735335
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg twice daily
Trial: 4613534
Drug: Quingestanol acetate
RxNorm normalized name: quinestradol
DrugBank: Quingestanol acetate (DB14679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quingestanol acetate 800 mcg in Mexico
Trial: 4613534
Drug: Quingestanol acetate
RxNorm normalized name: quinestradol
DrugBank: Quingestanol acetate (DB14679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quingestanol acetate 750 mcg in Chile and Peru
Trial: 28260598
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (weekly for five consecutive weeks at predefined acupuncture points: CV-3, CV-4, LR-8, SP-6, SP-9)
Trial: 24136731
Drug: ARA 290
RxNorm normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA 290 (daily subcutaneous administration for 28 days)
Trial: 21288841
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (12-week course of clarithromycin and rifabutin)
Trial: 19614943
Drug: Basic Lifestyle
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic Lifestyle Programme (BLP) targeting total daily steps
Trial: 10867599
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) via conventional pressurised metered-dose inhaler (pMDI) with spacer
Trial: 10867599
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (DPI and pMDI)
Trial: 3531220
Drug: Naloxone (NLX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (NLX; 0.08 mg/kg BW, iv)
Trial: 22537732
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy insomnia intervention
Trial: 22537732
Drug: Traditional depression-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional depression-focused treatment
Trial: 16171419
Drug: 4-factor solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-factor solution
Trial: 12234860
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg daily for 30 days
Trial: 2126396
Drug: Short-term continuous
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term continuous treatment with ST and TNL
Trial: 2126396
Drug: Long-term continuous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term continuous treatment with ST
Trial: 91889
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg naloxone (intervention)
Trial: 25531536
Drug: Voucher-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher-based treatment with motivational counseling (14 days of vouchers for complete smoking abstinence after a 5-day smoking reduction lead-in period)
Trial: 25531536
Drug: Voucher-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher-based treatment with motivational counseling (vouchers not contingent on abstinence)
Trial: 23884486
Drug: Itraconazole 200-mg
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200-mg tablet QD for 12 weeks
Trial: 23884486
Drug: Itraconazole 100-mg
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100-mg capsules QD for 12 weeks
Trial: 19302902
Drug: Cefepime IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime IV at a dose of 1 g q8h
Trial: 17403273
Drug: Inulin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (10 g/d) for 21 days
Trial: 15509187
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg plus colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with breakfast
Trial: 15509187
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg administered with breakfast, followed 4 hours later by colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with lunch
Trial: 15509187
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg administered with breakfast
Trial: 11813601
Drug: Locoregional immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional immunochemotherapy combined with systemic chemotherapy (Group A)
Trial: 11813601
Drug: Systemic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic immunotherapy combined with systemic chemotherapy (Group B)
Trial: 8064995
Drug: IINS (Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IINS (Insulin + Amino Acids)
Trial: 8064995
Drug: IIINS (Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIINS (Insulin + Higher Nitrogen Load)
Trial: 20882421
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg of elemental zinc per day for 5 days)
Trial: 15963089
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) 0.5 mg sublingual
Trial: 15963089
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg daily for 4 days
Trial: 12870063
Drug: Intravenous penicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin, 6 million units per day (one million unit every four hours) for seven days
Trial: 10571602
Drug: Simethicone (84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (84 mg t.d.s.)
Trial: 1905214
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and sucralfate (1 g by nasogastric tube every 4 hrs)
Trial: 1905214
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and ranitidine (50 mg iv every 6 hrs)
Trial: 1905214
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and sucralfate
Trial: 1905214
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and ranitidine
Trial: 26505163
Drug: Δ9‐THC (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ9‐THC (8 mg)
Trial: 26505163
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (5 mg/10 mg diazepam)
Trial: 25194996
Drug: Primary closure
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary closure of buccal mucosal graft harvest site
Trial: 25194996
Drug: Nonclosure of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonclosure of buccal mucosal graft harvest site
Trial: 17663046
Drug: Millimeter-range electromagnetic
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimeter-range electromagnetic radiation therapy
Trial: 9177976
Drug: Oxandrolone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.05 mg/kg/day)
Trial: 9177976
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low dose oxandrolone and oestrogen
Trial: 1609044
Drug: Bovine cortex
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine cortex phosphatidylserine (BC‐PS; 100 mg t.i.d.)
Trial: 3907394
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline sulphate 5 mg twice a day
Trial: 3907394
Drug: Ordinary tablets
RxNorm normalized name: phenazopyridine Oral Tablet [Azo Urinary Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary tablets 2.5 mg three times a day
Trial: 27015546
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (5 mg)
Trial: 27015546
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (5 mg)
Trial: 24693959
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus interlaminar epidural steroid injection
Trial: 24693959
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid injection
Trial: 22861076
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine patches (700 mg)
Trial: 16005120
Drug: Virosomal influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal influenza vaccine
Trial: 16104444
Drug: Conventional subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subunit vaccine
Trial: 12426518
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered once weekly (n = 17)
Trial: 12426518
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered 3 times weekly (n = 15)
Trial: 12426518
Drug: Epoetin administered
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin administered 3 times weekly (n = 15)
Trial: 12426518
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (once and three times weekly) and Epoetin (three times weekly)
Trial: 10233652
Drug: Chart as
RxNorm normalized name: Stachybotrys chartarum
DrugBank: Stachybotrys chartarum (DB10847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chart as an aide memoire for topical medications
Trial: 7805919
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) injection (1 mg/kg)
Trial: 1655177
Drug: Piroxicam 5
RxNorm normalized name: piroxicam 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 5 mg daily
Trial: 6336951
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 1.5 g three times daily for 5 days starting on the first day of menstruation
Trial: 6336951
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (DS) 50 mg three times on the first day followed by 25 mg three times daily for 4 days
Trial: 29539585
Drug: Exposure-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based Cognitive Behavioral Therapy (eb-CBT)
Trial: 27283792
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg subcutaneous (s.c.) relamorelin
Trial: 22262484
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day)
Trial: 22262484
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion during low sodium intake (LS; 30 mmol sodium/day)
Trial: 19075273
Drug: Chemotherapy (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (first cycle)
Trial: 19075273
Drug: Chemotherapy (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (second cycle)
Trial: 18080339
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg daily
Trial: 7666089
Drug: PVI 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVI 5‐FU 300 mg/m2/d plus IFN 5 MU subcutaneously three times weekly
Trial: 2759973
Drug: Ephedrine-caffeine mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine-caffeine mixture (1 mg/kg ephedrine, 2.5 mg/kg caffeine)
Trial: 25757446
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rectal diclofenac
Trial: 31612188
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral diclofenac
Trial: 31612188
Drug: 75 mg/3
RxNorm normalized name: cran/vitC/mannose/FOS/bromeln 3,875 mg/30 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/3 ml intramuscular diclofenac sodium
Trial: 31612188
Drug: 75 mg/3
RxNorm normalized name: cran/vitC/mannose/FOS/bromeln 3,875 mg/30 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/3 ml intravenous diclofenac
Trial: 28558714
Drug: ProF-Cog intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ProF-Cog intervention including falls risk assessment, tailored intervention (dementia care mapping, comprehensive geriatric assessment, occupational therapy, twice-weekly exercise for 6 months)
Trial: 25895497
Drug: Desmopressin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.3 μg/kg
Trial: 19436663
Drug: Rosuvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (5 mg) once daily
Trial: 10328277
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam (DZP) gel
Trial: 7001487
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg protacine 3-times daily for 21 days
Trial: 7001487
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oxyphenbutazone 3-times daily for 21 days
Trial: 7001487
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg protacine
Trial: 7001487
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oxyphenbutazone
Trial: 31809955
Drug: Torsemide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide (0.1 mg/kg PO q 12 h)
Trial: 31809955
Drug: Furosemide (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (2.0 mg/kg PO q 12 h)
Trial: 31809955
Drug: Diuretic groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic groups (Torsemide and Furosemide)
Trial: 26783233
Drug: Systematic clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic clinical testing including exercise testing, drug provocation, advanced cardiac imaging, and genetic testing.
Trial: 26783233
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator therapy.
Trial: 22622147
Drug: XELOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX plus bevacizumab using a dose-dense biweekly cycle (Q2W)
Trial: 11932561
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) treatment, 0.11-0.14 IU.kg-1, daily, s.c.
Trial: 11932561
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (standard therapy)
Trial: 7632064
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg/d)
Trial: 7632064
Drug: Griseofulvin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (1000 mg/d)
Trial: 2695448
Drug: 1-week interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week interval schedule of endoscopic injection sclerotherapy
Trial: 2695448
Drug: 2-week interval
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week interval schedule of endoscopic injection sclerotherapy
Trial: 19444731
Drug: Individual outpatient
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual outpatient alcoholism treatment
Trial: 19444731
Drug: Couples outpatient
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples outpatient alcoholism treatment
Trial: 12364460
Drug: GH 1
RxNorm normalized name: Cough 100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1 micro g/kg
Trial: 12364460
Drug: GH 3
RxNorm normalized name: Zicam Cough 3.3 MG/ACTUAT Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 3 micro g/kg
Trial: 12364460
Drug: GH 6
RxNorm normalized name: Zicam Cough 6 MG/ACTUAT Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 6 micro g/kg
Trial: 8021626
Drug: Bright colors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright colors (e.g., pink, blue, red)
Trial: 8021626
Drug: Dark colors
RxNorm normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark colors (e.g., brown, black, gray)
Trial: 2688780
Drug: Prescriptive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptive treatment
Trial: 2688780
Drug: Exploratory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory treatment
Trial: 26518352
Drug: Electric fan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric fan therapy
Trial: 23941470
Drug: Exercise-based programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-based programme (ARNI), 24 hours of one-to-one training by an Exercise Professional, plus at least 2 hours weekly unsupervised exercise, over 12-14 weeks
Trial: 21675444
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream, changed twice a day
Trial: 18608103
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (5 g/d)
Trial: 12401636
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of neostigmine plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Trial: 12401636
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of saline plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Trial: 7778354
Drug: physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physical therapy (cold foot-baths)
Trial: 647213
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (2.6 U/h)
Trial: 647213
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin infusion (10.6 U/h)
Trial: 647213
Drug: Both insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both insulin infusions (low and high dose)
Trial: 29462095
Drug: Topical testosterone
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical testosterone applied 3 times a week for 12 weeks
Trial: 29462095
Drug: Topical estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estrogen applied 3 times a week for 12 weeks
Trial: 11007214
Drug: PDT (Photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT (Photodynamic Therapy)
Trial: 27516420
Drug: PDL-PDT (Pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL-PDT (Pulsed Dye Laser-mediated Photodynamic Therapy)